318 related articles for article (PubMed ID: 30989487)
1. Successful hematopoietic stem-cell mobilization with plerixafor plus granulocyte-colony stimulating factor in multiple myeloma patients treated with pomalidomide.
Yoshifuji K; Toya T; Adachi H; Fujita M; Wada A; Konuma R; Kishida Y; Konishi T; Nagata A; Yamada Y; Kaito S; Kumagai T; Inamoto K; Akiyama M; Igarashi A; Najima Y; Doki N; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K
Int J Hematol; 2019 Jul; 110(1):115-118. PubMed ID: 30989487
[TBL] [Abstract][Full Text] [Related]
2. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
3. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
4. Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial).
Schmid A; Friess D; Mansouri Taleghani B; Keller P; Mueller BU; Baerlocher GM; Leibundgut K; Pabst T
Leuk Lymphoma; 2015 Mar; 56(3):608-14. PubMed ID: 24884311
[TBL] [Abstract][Full Text] [Related]
5. [Efficiency and safety analysis of Plerixafor combined with granulocyte colony-stimulating factor on autologous hematopoietic stem cell mobilization in lymphoma].
Ji MM; Shen YG; Gong JC; Tang W; Xu XQ; Zheng Z; Chen SY; He Y; Zheng X; Zhao LD; Zhao WL; Wu W
Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):112-117. PubMed ID: 36948864
[No Abstract] [Full Text] [Related]
6. Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.
Micallef IN; Stiff PJ; Nademanee AP; Maziarz RT; Horwitz ME; Stadtmauer EA; Kaufman JL; McCarty JM; Vargo R; Cheverton PD; Struijs M; Bolwell B; DiPersio JF
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1187-1195. PubMed ID: 29410180
[TBL] [Abstract][Full Text] [Related]
7. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
Chhabra S; Callander N; Watts NL; Costa LJ; Thapa B; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Anderson LD; Bal S; Dhakal B; Nathwani N; Shah N; Medvedova E; Bumma N; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Schmidt T; Orlowski RZ; Shain KH; Cowan AJ; Dholaria B; Cornell RF; Jerkins JH; Pei H; Cortoos A; Patel S; Lin TS; Usmani SZ; Richardson PG; Voorhees PM
Transplant Cell Ther; 2023 Mar; 29(3):174.e1-174.e10. PubMed ID: 36494017
[TBL] [Abstract][Full Text] [Related]
8. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.
Flomenberg N; Comenzo RL; Badel K; Calandra G
Biol Blood Marrow Transplant; 2010 May; 16(5):695-700. PubMed ID: 20067838
[TBL] [Abstract][Full Text] [Related]
9. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.
Duarte RF; Shaw BE; Marín P; Kottaridis P; Ortiz M; Morante C; Delgado J; Gayoso J; Goterriz R; Martínez-Chamorro C; Mateos-Mazón JJ; Ramírez C; de la Rubia J; Achtereekte H; Gandhi PJ; Douglas KW; Russell NH
Bone Marrow Transplant; 2011 Jan; 46(1):52-8. PubMed ID: 20305700
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.
Kumar SK; Mikhael J; Laplant B; Lacy MQ; Buadi FK; Dingli D; Gertz MA; Laumann K; Miceli T; Mahlman M; Bergsagel LP; Hayman SR; Reeder C; Stewart AK; Dispenzieri A; Gastineau DA; Winters JL
Bone Marrow Transplant; 2014 Feb; 49(2):201-5. PubMed ID: 24185588
[TBL] [Abstract][Full Text] [Related]
11. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
[TBL] [Abstract][Full Text] [Related]
12. Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.
Costa LJ; Abbas J; Hogan KR; Kramer C; McDonald K; Butcher CD; Littleton A; Shoptaw K; Kang Y; Stuart RK
Bone Marrow Transplant; 2012 Nov; 47(11):1403-8. PubMed ID: 22484324
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience.
Jantunen E; Kuittinen T; Mahlamäki E; Pyörälä M; Mäntymaa P; Nousiainen T
Eur J Haematol; 2011 Apr; 86(4):299-304. PubMed ID: 21198864
[TBL] [Abstract][Full Text] [Related]
14. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.
DiPersio JF; Stadtmauer EA; Nademanee A; Micallef IN; Stiff PJ; Kaufman JL; Maziarz RT; Hosing C; Früehauf S; Horwitz M; Cooper D; Bridger G; Calandra G;
Blood; 2009 Jun; 113(23):5720-6. PubMed ID: 19363221
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.
Samaras P; Pfrommer S; Seifert B; Petrausch U; Mischo A; Schmidt A; Schanz U; Nair G; Bargetzi M; Taverna C; Stupp R; Stenner-Liewen F; Renner C
Biol Blood Marrow Transplant; 2015 Jan; 21(1):74-80. PubMed ID: 25278456
[TBL] [Abstract][Full Text] [Related]
16. Plerixafor (Mozobil).
Med Lett Drugs Ther; 2010 Apr; 52(1335):27-8. PubMed ID: 20360661
[No Abstract] [Full Text] [Related]
17. Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide.
Micallef IN; Ho AD; Klein LM; Marulkar S; Gandhi PJ; Calandra G; McSweeney PA
Bone Marrow Transplant; 2011 Mar; 46(3):350-5. PubMed ID: 20479709
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of residual plerixafor for second-day stem cell mobilization in multiple myeloma patients.
He D; Zhu C; Guo X; Huang X; Han X; Zheng G; Zhao Y; Yang Y; Wu W; Ge J; Zhang E; He J; Cai Z
Transfus Apher Sci; 2023 Jun; 62(3):103618. PubMed ID: 36481258
[TBL] [Abstract][Full Text] [Related]
19. Low baseline platelet count predicts poor response to plerixafor in patients with multiple myeloma undergoing autologous stem cell mobilization.
Bakeer M; Zubair AC; Roy V
Cytotherapy; 2020 Jan; 22(1):16-20. PubMed ID: 31879152
[TBL] [Abstract][Full Text] [Related]
20. Plerixafor dosing and administration in a patient with dialysis-dependent renal failure.
Gregory KM; Rao KV; Armistead PM
Ann Pharmacother; 2010 Dec; 44(12):2028-30. PubMed ID: 21098756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
